← Back to Search

Hormone Therapy

Hormone Therapy for Obesity

N/A
Waitlist Available
Led By Jonathan Q. Purnell, M.D.
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
40 postmenopausal women (age 40-62) and 30 men (age 18-45) who are healthy, at their lifetime maximal weight, have been weight stable for at least six months prior to entry, have a BMI between 19 and 39.9 kg/m2, and are willing to commit to not making significant changes to their diet or daily activities while enrolled in the study.
Be between 18 and 65 years old
Must not have
Subjects with psychiatric illness (i.e., depression, psychosis, bipolar, schizophrenia; or are taking medications for these disorders)
Any subject with previously unevaluated postmenopausal bleeding
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 10 Other Conditions
All Individual Drugs Already Approved

Summary

This trialinvestigates if hormones affect how fat is stored in the body and how stress hormones are affected.

Who is the study for?
This trial is for postmenopausal women aged 40-62 and men aged 18-45 who are healthy, at their heaviest lifetime weight, stable in weight for the past six months, with a BMI of 19 to 39.9. Participants must not plan diet or activity changes during the study. Exclusions include those with certain diseases, metal implants, endocrine disorders, abnormal bleeding or prostate issues; also excluded are heavy drinkers, smokers, frequent exercisers and those on blood thinners.
What is being tested?
The study tests if estrogen cream or testosterone (via Depo Lupron/Aromatase inhibitor) affects cortisol levels and fat distribution compared to placebos (placebo injection/cream). It's designed to see how these hormones might influence body composition after menopause in women and in younger men.
What are the potential side effects?
While specific side effects aren't listed here, generally hormone treatments like estrogen can cause mood swings, skin irritation where applied; testosterone may affect mood and increase acne risk. Placebos typically have no active ingredients but can lead to perceived side effects due to expectations.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a healthy postmenopausal woman aged 40-62 or a man aged 18-45, at my heaviest weight, with a stable weight and BMI between 19 and 39.9, and I can maintain my current diet and activity levels.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a psychiatric illness or am taking medication for one.
Select...
I have had bleeding after menopause that hasn't been checked.
Select...
I am on blood thinners or have had an abnormal exam result.
Select...
I have an untreated hormone disorder affecting my body's fat and muscle.
Select...
I cannot use estrogen due to health reasons.
Select...
I have had a prostate exam in the last year.
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

5Treatment groups
Active Control
Placebo Group
Group I: 2Active Control1 Intervention
Men who receive Depo Lupron for 4 months, then are replaced with testosterone and aromatase inhibitor for 4 months.
Group II: 3Active Control1 Intervention
Men who receive Depo Lupron for 4 months, then are replaced with testosterone and placebo for 4 months.
Group III: 5Active Control1 Intervention
Women on estrogen cream
Group IV: 1Placebo Group1 Intervention
Men on placebo injections for 4 months
Group V: 4Placebo Group1 Intervention
Women on placebo cream

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
1,006 Previous Clinical Trials
7,413,779 Total Patients Enrolled
29 Trials studying Obesity
9,206 Patients Enrolled for Obesity
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,450 Previous Clinical Trials
4,332,377 Total Patients Enrolled
469 Trials studying Obesity
589,871 Patients Enrolled for Obesity
Jonathan Q. Purnell, M.D.Principal InvestigatorOHSU - Center for the Study of Weight Regulation
4 Previous Clinical Trials
123 Total Patients Enrolled
4 Trials studying Obesity
123 Patients Enrolled for Obesity

Media Library

Depo Lupron/Aromatase inhibitor (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00694733 — N/A
Obesity Research Study Groups: 1, 2, 3, 4, 5
Obesity Clinical Trial 2023: Depo Lupron/Aromatase inhibitor Highlights & Side Effects. Trial Name: NCT00694733 — N/A
Depo Lupron/Aromatase inhibitor (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00694733 — N/A
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top